Skip to content

Intraoperative Radiotherapy in Treating Spinal Metastases

The Efficacy and Safety of Intraoperative Radiotherapy Vesus Stereotactic Body Radiotherapy in Managing Spinal Metastases: A Prospective, Single-center, Open-label, Non-inferior, Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06093854
Enrollment
132
Registered
2023-10-23
Start date
2024-01-31
Completion date
2027-01-31
Last updated
2023-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Metastases

Keywords

spinal metastases, intraoperative radiotherapy, stereotactic body radiotherapy, decompression surgery

Brief summary

In order to provide theoretical evidence for the comprehensive and standardized treatment of spinal metastases with pathological fractures and/or spinal cord compression, the investigators conduct this trial to investigate the efficacy and safety of IORT and postoperative SBRT in adjuvant treatment of metastatic spinal tumors after posterior decompression surgery by recruiting patients with spinal metastases who met the inclusion criteria, and randomly divided them into the following treatment cohorts: 1) decompression surgery + IORT (15-20 Gy, 20-50min); 2) decompression surgery and postoperative SBRT(30Gy, 5 fractions, 3 weeks).

Detailed description

Spine is the most common metastatic site for advanced malignancies, accounting for about 70% of all patients with bone metastasis. Approximately 40% -70% of patients with advanced cancer eventually develop spinal metastases. Spinal metastases require multidisciplinary treatments, and surgical decompression surgery is the preferred treatment in managing spinal metastases with bone related events, especially those with spinal cord compression. The purpose of decompression surgery is to directly relieve nerve compression, alleviate pain, rebuild spinal stability, and reduce tumor burden, which improves the quality of life, and extend the life span indirectly. At the same time, radiotherapy is also an indispensable treatment for spinal metastases after surgical decompression. The purpose of radiotherapy is to remove residual tumor lesions, alleviate pain, and prevent further pathological fractures. Recent years have witnessed the rapid development of stereotactic bone radiotherapy (SBRT). As reported, SBRT can not only increase the radiation dose at the tumor site, but also reduce radiation damage to the spinal cord and surrounding normal tissues, which is the preferred adjuvant treatment for patients with metastatic spinal tumors. However, SBRT has the several risks, including radiation myelitis, delayed vertebral pathological fractures, local skin allergies, radiotherapy side effects in the esophagus and lungs, and duodenal perforation. Moreover, stereotactic radiotherapy technology has higher costs compared to traditional external beam radiotherapy. Recently, the application of intraoperative radiotherapy (IORT) can effectively reduce the direct radiation for surrounding normal tissues and maximally eliminate the residual tumor cells. The advantages of IORT include: ① immediate reduction of the possibility of tumor cell expansion after surgery; ② Safe direct radiation and effective protection of normal tissues beyond the radiation depth; ③ To effectively protect adjacent normal tissues, light-limiting tubes with different diameters can be selected based on the size and range of tumor; ④ Shortening treatment course with lower costs and better compliance; ⑤ Slight systemic side effects and bone marrow suppression. To the knowledge, no research focuses on the efficacy of IORT and SBRT in the adjuvant treatment of spinal metastases. Therefore, in order to provide theoretical evidence for the comprehensive and standardized treatment of spinal metastases with pathological fractures and/or spinal cord compression, the investigators conduct this trial to investigate the efficacy and safety of IORT and postoperative SBRT in adjuvant treatment of metastatic spinal tumors after posterior decompression surgery by recruiting patients with spinal metastases who met the inclusion criteria, and randomly divided them into the following treatment cohorts: 1) decompression surgery + IORT (15-20 Gy, 20-50min); 2) decompression surgery and postoperative SBRT(30Gy, 5 fractions, 3 weeks).

Interventions

Intraoperative radiotherapy (IORT, 15-20 Gy, 20-50min)

RADIATIONStereotactic body radiotherapy (SBRT)

postoperative stereotactic body radiotherapy (SBRT, 30Gy, 5 fractions, 3 weeks)

Sponsors

Shanghai Changzheng Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

1. Decompression surgery + IORT (15-20 Gy, 20-50min) 2. Decomression surgery + postoperative SBRT ( 30Gy, 5 fractions, 3 weeks)

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of spinal metastases; * Estimated survival time more than 3 months; * The spinal instability neoplastic score (SINS) \>12; * The general condition allows to recieve surgery; * Single or multiple metastatic lesions with only one site presenting epidural spinal cord compression; * signed informed consent.

Exclusion criteria

* Clinical diagnosis of primary spinal tumors; * Presence of metastases in central nerve system; * Isolated lesion undergoing en bloc resection; * Mental disorder and/or intellectual dificiency; * Refusing to accept follow-up; * without signing informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Local control rate2 yearsThe local control of tumor in the surgical field

Secondary

MeasureTime frameDescription
Health-related quality of life2 yearsThe Functional Assessment of Cancer Therapy -General (FACT-G) Scale (Minimum: 0; Maximum: 108 ) is utilized to evaluate the health-related quality of life after treatments, and higher scores mean a worse outcome.
Progression-free survival2 yearsThe survival time between the day after treatments and the date of any evidence proving tumor progression or final follow-up
Overall survival2 yearsThe survival time between the day after treatments and the date of all-cause death or final follow-up
Radiation-related complications2 yearsThe complications assciated with the radiation process

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026